SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC

Clinical trial NCT06889649 · RECRUITING

Trial details

NCT number: NCT06889649
Sponsor: Peking University First Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Radiation Therapy Targeted Therapy Immunotherapy Renal Cancer Metastatic

Start date: 2019-01-01
Primary completion: 2027-02-28
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.